Solitary Fibrous Tumor – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Solitary Fibrous Tumor Emerging Therapy and TPP Insights

Thelansis’s “Solitary Fibrous Tumor Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Solitary Fibrous Tumor Overview

Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can arise in various anatomical sites, including the pleura, soft tissues, and central nervous system. Most tumors harbor a NAB2–STAT6 gene fusion, a molecular hallmark that promotes abnormal transcriptional signaling. Clinical behavior ranges from slow-growing localized disease to tumors capable of recurrence or distant metastasis, sometimes years after initial treatment. Symptoms depend on tumor location and may include pain, pressure effects, or organ-specific dysfunction, while some lesions are detected incidentally. Complete surgical resection remains the preferred treatment for localized disease, with radiotherapy considered in selected cases. For unresectable or metastatic SFT, antiangiogenic agents such as pazopanib and sunitinib can provide disease control, while chemotherapy may be appropriate in selected settings, particularly for dedifferentiated tumors. Because late recurrence is possible and evidence for systemic treatments remains limited, long-term surveillance and specialist multidisciplinary care are essential.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)